Novo Nordisk’s diabetes drug Ozempic may reduce the risk of Alzheimer’s disease, study says
The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer's diagnosis in
Read More
Alzheimer's disease
Alzheimer’s drug Leqembi promises to give patients more time, but they face a long road to treatment
Leqembi's rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and regular brain scans, among others.
Read More
Medicare will pay for Alzheimer’s drug Leqembi. What patients and doctors should know
Patients with early Alzheimer's disease could still pay more than $5,000 in out-of-pocket costs for Leqembi even with Medicare coverage.
Read More
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
Analysts believe the Medicare registry requirement and new guidance on Leqembi's prescription label could potentially weigh on sales in the
Read More
US FDA approves new Alzheimer's drug Leqembi
Drug slows cognitive decline by about 27% over 18 months, says Food and Drug Administration Source link
Read More
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling
Read More
FDA advisors endorse Alzheimer’s treatment Leqembi paving way for full approval this summer
Medicare has promised to broadly cover Leqembi, which costs $26,500 per year, if the FDA grants full approval of the
Read More
Alzheimer’s treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
The authors said the estimated cost of Leqembi to Medicare are conservative, and spending on the Alzheimer's treatment may increase
Read More